Your browser doesn't support javascript.
loading
Primary prophylaxis was associated with lower arthropathy in Colombian men with haemophilia B: A longitudinal analysis (2015-2019).
Hernández Vargas, Juliana Alexandra; Linares, Adriana; Solano, María Helena; Valbuena, Ana María; Acuña, Lizbeth.
Afiliação
  • Hernández Vargas JA; Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia.
  • Linares A; Clinica Infantil Colsubsidio and Fundación Hospital de la Misericordia, Bogotá, Colombia.
  • Solano MH; Department of Pediatrics, Universidad Nacional de Colombia, Bogotá, Colombia.
  • Valbuena AM; Hospital de San José, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.
  • Acuña L; Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia.
Haemophilia ; 26(6): e282-e290, 2020 Nov.
Article em En | MEDLINE | ID: mdl-32892455
INTRODUCTION: The risk of chronic haemophilic arthropathy (CHA) is related to severity. Evidence suggests that primary prophylaxis (PPr) could reduce CHA incidence and its impact on quality of life. AIM: To evaluate the association between PPr and CHA in Colombian males with haemophilia B (HB) during 2015 to 2019. METHODS: A panel-time analysis was performed with data provided by the National Health System to update a nationwide open cohort of people with congenital coagulopathies. The association was evaluated in a logistic random-effect regression model (LRERM), adjusted by age at diagnosis, prophylaxis dose and frequency, severity, haemarthrosis and high-titre inhibitors. RESULTS: During 2015-2019, a total of 362 men with HB and treated with either, primary, secondary or tertiary prophylaxis were identified. At baseline, CHA prevalence in the cohort was 36.84% (n = 133), median age was 19.0 years (IQR: 10.0-27.0), and median age at diagnosis was 1.0 year (IQR: 0.0-4.0). PPr was prescribed in 37.85% (n = 137), and median dose (IU/Kg/dose) was almost the same for primary vs. secondary/tertiary prophylaxis. Patients in PPr had a lower frequency of severe HB, CHA, haemarthrosis, infectious complications and high-titre inhibitors than those in secondary or tertiary prophylaxis (STPr). In the LRERM, PPr was associated with a significant reduction of 89.70% in the odds of CHA (aOR = 0.103, IC 95%: 0.040, 0.270; P < .001), compared with STPr. CONCLUSIONS: PPr decreased the odds of CHA by 89.70% in males with HB in Colombia. Our findings are consistent with previous studies and support the strategy to prescribe PPr to our patients.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Hemofilia B / Artropatias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Child / Child, preschool / Humans / Infant / Male País/Região como assunto: America do sul / Colombia Idioma: En Revista: Haemophilia Assunto da revista: HEMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Hemofilia B / Artropatias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Child / Child, preschool / Humans / Infant / Male País/Região como assunto: America do sul / Colombia Idioma: En Revista: Haemophilia Assunto da revista: HEMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido